What the headline success figures actually mean

The most immediate question when weighing any treatment is whether it actually works. For ChondroFiller, published clinical series consistently report significant symptom relief in 70–85% of patients, with satisfaction exceeding 80% in most cohorts — a useful practical benchmark at the decision stage.

Knee outcomes are the best documented. A 2024 study by Simeonov (n=17, mean age 31) recorded statistically significant improvements on both the IKDC and Lysholm scales at 3, 6, and 12 months (p<0.05). Across broader series, the average IKDC score rises from approximately 48 before treatment to around 80 at three years — a 30-point gain that, in functional terms, typically represents a shift from moderate activity limitation (struggling with stairs, unable to jog) to near-normal daily and recreational activity. The Simeonov cohort showed a plateau between 6 and 12 months, suggesting most of the functional benefit consolidates within the first year rather than accumulating indefinitely.

Hip data tell a comparable story. A prospective cohort of 26 patients with acetabular cartilage lesions, followed for 12–60 months, found 17 of 21 evaluable participants (81%) achieved good or excellent results, with a mean Harris Hip Score gain of +33 points.

It is worth stating clearly that the evidence, while encouraging, rests on smaller prospective series rather than large randomised trials. The figures above represent realistic central estimates, not guarantees — and outcomes vary meaningfully with patient selection, a point the following sections address directly.

How cartilage quality is measured — and what the scans show

Pain scores tell part of the story. What imaging and direct tissue assessments add is an independent check on whether improved symptoms reflect genuine cartilage repair — or simply better pain tolerance.

Three grading tools appear most often in ChondroFiller studies. MOCART is an MRI-based score that rates how well regenerated cartilage fills a defect and integrates with surrounding tissue. Outerbridge and ICRS grades, assessed during arthroscopy, describe the physical surface condition: grade 0 is normal; grade 3–4 means significant fissuring or exposed bone.

The most direct cartilage-quality evidence comes from a 2025 wrist study in which treated patients underwent follow-up arthroscopy. ChondroFiller-treated surfaces averaged Outerbridge 1.5 against 3.0 in untreated controls (P=0.006); ICRS grading showed grade 1 versus grade 3 (P=0.002). Grade 1 represents near-normal cartilage with only minor softening; grade 3 means substantial surface damage. That is a clinically meaningful difference between a repaired and a deteriorating surface, not a statistical footnote.

MRI data across published knee and hip series show MOCART scores in the range of 70–87, consistent with good defect filling and tissue integration. These imaging findings corroborate the symptom improvements noted in the published series, and appear to continue maturing beyond the functional plateau seen at around six to twelve months — suggesting tissue quality consolidates even after pain relief has largely stabilised.

Why the mechanism matters — and how it differs from microfracture

ChondroFiller works through a process called acellular matrix-induced chondrogenesis. The scaffold itself contains no donor cells; instead, it acts as a three-dimensional framework that progenitor cells — drawn from the synovium and subchondral bone — migrate into and colonise after placement. A 2025 ex vivo osteochondral model quantified this recruitment, recording a 2.4-fold increase in DNA content within the scaffold by day 14, confirming that cellular ingrowth is active rather than passive.

Microfracture, still widely used as a reference technique, works differently. By perforating the subchondral bone, it triggers a blood-clot repair response that fills the defect with fibrocartilage — a stiffer, less resilient tissue that functions adequately in the short term but whose mechanical properties typically decline beyond two to three years. ChondroFiller targets hyaline-like tissue formation rather than fibrocartilage, which is the closer biological match to native articular cartilage.

The practical implication is that the two approaches are not interchangeable alternatives. ChondroFiller is also distinct from symptomatic fillers or joint lubricants: it is a regenerative scaffold, not a cushioning or pain-blocking agent. The MOCART maturation curves documented in published series — where tissue quality continues to consolidate after functional scores plateau — give biological plausibility to the prospect of longer-term benefit that symptomatic measures alone would not capture.

Which patients see the best results

Three factors consistently predict a favourable outcome: defect size, patient age, and the condition of the surrounding joint.

The strongest case for treatment rests on focal, isolated lesions under 2 cm². Smaller defects allow the scaffold to integrate with healthy cartilage on all sides — a structural advantage that larger or diffuse damage cannot offer. Published clinical series cover the knee and hip most thoroughly, with encouraging early data from the ankle and small wrist joints, though the knee and hip evidence base is the more mature of the two.

Across those series, best-responding patients fall broadly within the 18–55 age range. Younger, active individuals tend to retain the progenitor cell activity the scaffold depends on for colonisation, and the tissue remodelling capacity needed to support longer-term maturation. A shorter pre-operative symptom history also favours a stronger response — prolonged symptoms often reflect progressive deterioration that narrows the biological repair window before treatment begins.

The principal contraindication is advanced osteoarthritis. Hip series following patients for up to five years found consistently poor outcomes in those with Tönnis grade 2–3 changes; the same principle applies to generalised knee degeneration. Widespread joint disease alters the local biological environment such that durable scaffold integration becomes unlikely — a repair-environment limitation, not simply a procedural one.

One clinician-side quality variable worth noting alongside patient selection is application precision. Placing the scaffold flush with the surrounding cartilage surface is technically important; overfilling has been associated with fibrous rather than hyaline-like tissue in published series. This is an image-guidance consideration rather than a risk the patient weighs directly, but it underlines why appropriate clinical setting matters for this treatment pathway.

Where the evidence still has gaps

The clinical picture is encouraging — but as with most newer techniques, the evidence base is still building.

The most significant structural gap is the absence of a large randomised controlled trial. The only RCT published to date (2016) enrolled 23 patients and was hampered by high dropout in the microfracture control arm, making direct statistical comparison between the two approaches unreliable. Well-powered head-to-head data do not yet exist.

Durability is a related question. Published follow-up extends to five years in the strongest cohort series, but data beyond that point are thin. Whether the quality of regenerated tissue holds over the longer term remains to be confirmed by extended registry evidence.

A 2024 in-vitro biomechanical study adds a practical note: during the early weeks after treatment, the gel does not protect the opposing cartilage surface under cyclic loading because the scaffold has not yet stabilised. This is precisely why the post-treatment weight-bearing protocol matters — not as an arbitrary restriction, but as a direct consequence of how the scaffold integrates. Following the activity guidance provided after treatment is a material part of the outcome, not a precaution that can safely be shortened.

ChondroFiller holds CE marking as a Class III medical device and is in established use across Europe; it carries no FDA approval and is unavailable in the United States. More than 19,000 procedures have been performed globally, though post-market registry data have not yet been published to the standard of a prospective cohort study — a gap that ongoing real-world use, if captured systematically, will progressively narrow.

What this means at the point of your decision

Taken together, the published evidence positions ChondroFiller as a reasonable scaffold option when the clinical picture fits — a focal lesion in an otherwise intact joint, not yet progressed to widespread degeneration. The decision, though, turns on assessment rather than the headline success rate alone: defect geometry, joint-loading patterns, and the health of surrounding tissue all influence appropriateness, and none of those factors can be reliably established without imaging and a structured consultation. That is the practical takeaway the evidence supports — not that ChondroFiller works for everyone, but that for the right patient profile it offers a biologically coherent, well-tolerated pathway with consistent outcome data across multiple joints and follow-up periods up to five years.

For patients who want to explore whether they fit that profile, the MSK Doctors team at Sleaford and Grantham can carry out this assessment without a GP referral; where ChondroFiller or a combination approach is judged appropriate, it is delivered as an ultrasound-guided injectable scaffold in an outpatient setting. Initial consultations can be booked directly at mskdoctors.com.

1. [1] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint (Simeonov 2024). (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Arthroscopic utilization of ChondroFiller gel for hip articular cartilage defects: 12–60-month follow-up (2021). (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
3. [3] Controlled randomized multicenter study: ChondroFiller liquid vs microfracture for focal cartilage defects of the knee (2016). (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Cartilage reconstruction using ChondroFiller in intra-articular distal radius fractures (2025). (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
5. [5] Influence of cartilage defects and collagen gel on intact cartilage integrity: biomechanical in-vitro study (2024). (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
6. [6] Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration (2025). (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759